prikaz prve stranice dokumenta GSTP1 and prostate cancer
  Download
PDF 769.88 KB
master's thesis
GSTP1 and prostate cancer
equivalent
Zagreb: University of Zagreb, School of Medicine, 2022. urn:nbn:hr:105:152462
Mulabdić, Denis
University of Zagreb
School of Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Mulabdić, D. (2022). GSTP1 and prostate cancer : equivalent (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:152462

Mulabdić, Denis. "GSTP1 and prostate cancer : equivalent." Master's thesis, University of Zagreb, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:105:152462

Mulabdić, Denis. "GSTP1 and prostate cancer : equivalent." Master's thesis, University of Zagreb, School of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:105:152462

Mulabdić, D. (2022). 'GSTP1 and prostate cancer : equivalent', Master's thesis, University of Zagreb, School of Medicine, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:105:152462

Mulabdić D. GSTP1 and prostate cancer : equivalent [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2022 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:105:152462

D. Mulabdić, "GSTP1 and prostate cancer : equivalent", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:105:152462

Metadata
TitleGSTP1 and prostate cancer : equivalent
Title (croatian)GSTP-1 u karcinomu prostate : ekvivalent
AuthorDenis Mulabdić
MentorMonika Ulamec (mentor)
Committee memberMonika Ulamec (predsjednik povjerenstva)
Committee memberBožo Krušlin (član povjerenstva)
Committee memberLjiljana Šerman (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
Zagreb
Defense date and country2022-01-31, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract
Prostate cancer is a widespread disease that currently has no accurate diagnostic markers. Its early identification is important for treatment in its initial stages and prevention of metastatic progression. The inability of the current PSA biomarker to distinguish between benign prostatic hyperplasia and prostate cancer has led to overdiagnosis and unnecessary biopsies, fuelling research to discover novel biomarkers. Our study considers the prospect of using the GSTP1 gene as a marker to differentiate between prostatic carcinomas and hyperplasia states. In our study, we analyzed biopsies of 20 patients with BPH and 20 biopsies of patients with PCa, assessing GSTP1 hypermethylation events at five CpG sites. We observed statistically significant differences in methylation patterns between BPH and PCa and were able to positively correlate methylation to tPSA and age. Furthermore, PCa CpG islands were consistently more hypermethylated than BPH tissues, and interestingly, PCa tumour-adjacent tissue (TAT) showed a similar progression towards hypermethylation states compared to BPH. These results were also confirmed when assessing the GSTP1 protein expression, which was absent in PCa, but was present in BPH and TAT. Concerning our results, we think that this marker would be an excellent candidate to enhance current diagnostic tools in PCa identification.
Abstract (croatian)
Rak prostate je maligna bolest s visokom incidencijom i mortalitetom. Istraživanja su usmjerena na pronalazak preciznijih dijagnostičkih i prognostičkih markera. Rano otkrivanje raka prostate je važno zbog liječenje bolesti u početnim fazama kao i za prevencije metastatske progresije. Niska specifičnost biomarkera PSA koji se rutinski koristi u dijagnostici te njegova nemogućnost dobrog razlikovanja stanja poput benigne hiperplazije (BPH), upale prostate i raka dovodi do nepotrebnih biopsija i generiranja troškova zdravstvenog sustava. Naša studija razmatra mogućnost upotrebe metilacijskog obrasca gena GSTP1 kao markera za razlikovanje karcinoma od BHP. Analizirali smo tkivo biopsija 20 pacijenata s BPH i 20 biopsija pacijenata s PCa, procjenjujući metilacijski obrazac GSTP1 na pet CpG mjesta, kao i imunohistokemijsku izraženost proteina GSTP. Naši rezultati pokazuju statistički značajne razlike u obrascima metilacije između BPH i PCa koja je pozitivno povezana i s tPSA te s dobi. U PCa CpG otoci bili su stalno hipermetilirani u odnosu na BPH u tkivu, a zanimljivo je da okolno peritumorsko tkivo (TAT) pokazuje sličan napredak prema hipermetilacijskim obrascima u odnosu na BPH. Ti su rezultati također potvrđeni prilikom procjene ekspresije proteina GSTP1, koji pokazuje potpuni nedostatak izraženosti u PCa, ali je prisutan u BPH i TAT. Temeljem rezultata naše studije GSTP1 je odličan kandidat za poboljšanje postojećih dijagnostičkih alata u identifikaciji PCa.
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:105:152462
ProjectNumber: UIP-2017-05-8138
Title: Epigenetički biomarkeri raka prostate
Acronym: epiPro
Leader: Nino Sinčić
Jurisdiction: Croatia
Funder: HRZZ
Funding stream: UIP
Study programmeTitle: Medicine (in English language)
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Public noteDekanova nagrada 2020./2021.
Created on2022-12-20 12:06:17